AKT3: RAC-gamma serine/threonine-protein kinase
AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on AKT3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Rupitasertib | Phase 2 | Merck KGaA | Small molecule | InhibitorSerine/threonine-protein kinase AKT3 inhibitor | 0 |
- Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 20.80
- Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome0.67
- Breast cancer0.57
- Schizophrenia0.48
- Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 10.47
- Overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes0.46
- Glioma0.45
- Neoplasm0.45
- Obesity disorder0.43
- Smoking initiation0.42
- Cancer0.41
- Risk-taking behaviour0.40
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4816, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q9Y243, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets